What is Wedbush’s Estimate for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share estimates for Wave Life Sciences in a research report issued on Tuesday, April 8th. Wedbush analyst Y. Zhong anticipates that the company will earn ($0.27) per share for the quarter. Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. Wedbush also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.04) EPS and FY2026 earnings at ($1.14) EPS.

WVE has been the subject of several other research reports. StockNews.com raised Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Finally, Jefferies Financial Group assumed coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They issued a “buy” rating and a $26.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Wave Life Sciences has an average rating of “Moderate Buy” and a consensus price target of $22.18.

Wave Life Sciences Trading Up 3.1 %

Shares of WVE opened at $5.65 on Friday. The firm has a fifty day simple moving average of $9.44 and a two-hundred day simple moving average of $11.66. The firm has a market cap of $867.20 million, a PE ratio of -5.09 and a beta of -0.93. Wave Life Sciences has a 1-year low of $4.25 and a 1-year high of $16.74.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.34. The firm had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.

Institutional Trading of Wave Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in Wave Life Sciences in the 4th quarter worth approximately $40,000. Quarry LP purchased a new position in shares of Wave Life Sciences in the fourth quarter worth $62,000. KBC Group NV bought a new position in shares of Wave Life Sciences during the fourth quarter worth $67,000. Summit Investment Advisors Inc. grew its stake in Wave Life Sciences by 31.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock valued at $119,000 after acquiring an additional 2,308 shares in the last quarter. Finally, Westwood Wealth Management purchased a new position in Wave Life Sciences during the fourth quarter valued at $124,000. Institutional investors own 89.73% of the company’s stock.

Insider Buying and Selling at Wave Life Sciences

In other news, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. This trade represents a 33.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the transaction, the director now directly owns 16,115 shares of the company’s stock, valued at $157,443.55. This represents a 39.45 % decrease in their position. The disclosure for this sale can be found here. Insiders own 29.10% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.